Dose Insider / Glossary / GLP-1 tachyphylaxis

TachyphylaxisWhich effects of GLP-1 medicines fade, and which do not

Updated November 20, 2026 · 4 min read · Nauck 2021; Zepbound, Mounjaro and Byetta labels; Urva 2020; Friedrichsen 2021

Tachyphylaxis is the weakening of a drug's effect with repeated doses. With GLP-1 medicines the word comes up for one effect in particular: the slowing of the stomach.

29%10 mg, nausea on Zepbound
Nausea on ZepboundWeight trials, % of people, by dose10 mg29%15 mg28%5 mg25%Placebo8%Nausea on ZepboundWeight trials, % of people, by dose10 mg29%15 mg28%5 mg25%Placebo8%

Most nausea came during the dose climb and decreased over time.

On this page

A 2021 review notes that the effect of long-acting GLP-1 medicines on gastric emptying decreases over time, and the Zepbound and Mounjaro labels say the delay is largest after the first dose and diminishes after that.1,2,3 The effects on weight and blood sugar, by contrast, last for as long as the medicine is taken.

The stomach effect fades

The study behind the tirzepatide labels, run by the drug's maker, found that once-weekly tirzepatide delayed gastric emptying after a single dose and that the effect diminished after several doses in healthy volunteers. In people with type 2 diabetes on a rising dose, some delay remained after multiple doses.4 For semaglutide 2.4 mg, a 20-week trial measured emptying with paracetamol, a liquid-phase test, and found no evidence of slower emptying than on placebo at week 20.5

The 2021 review explains why this matters for the class. Short-acting medicines such as twice-daily exenatide keep their effect on gastric emptying during long-term treatment, while long-acting ones lose part of it. The short-acting medicines, in turn, have weaker effects on overnight and fasting blood sugar.1

Side effects follow the same curve

The most common side effects ease in a similar way. The Zepbound label says most nausea, vomiting and diarrhea happened during the dose climb and decreased over time; in its weight trials nausea was reported by 25%, 29% and 28% on 5, 10 and 15 mg, against 8% on placebo.2 The Byetta label says that nausea usually decreases over time.6 That is the reason every GLP-1 label raises the dose in steps: each step gives the body time to adjust before the next.

Weight and blood sugar do not fade

The withdrawal trials show the main effects persist. Both took people who had already been on the drug for months and split them at random: some stayed on it, and the rest were switched to placebo without knowing.

If the weight effect wore off after months of use, the people who stayed on the drug would have drifted back toward the placebo group. They moved the other way.

A weight plateau is sometimes called tachyphylaxis, but the trials describe it differently. Weight levels off because the body's appetite feedback pushes back as weight falls, and a 2024 modelling study found that GLP-1 medicines weaken that push-back rather than losing their own effect.9 Our page on the Zepbound plateau covers it.

What it means in practice

Our page on nausea on a GLP-1 covers what helps in the first weeks.

Sources

  1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
  3. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
  4. Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886-1891. doi:10.1111/dom.14110
  5. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
  6. BYETTA (exenatide) injection prescribing information. AstraZeneca; DailyMed, version published September 8, 2025; highlights and section 5. dailymed.nlm.nih.gov
  7. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
  8. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
  9. Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring) 2024;32:1163-1168. doi:10.1002/oby.24027

Related analyses

Log nausea and fullness with each dose and see how they change as weeks pass.

Open Dose Insider